Lisocabtagene Maraleucel,ibrutinib,venetoclax
Bms,Roche,Abbvie,janssen
['liso-cel', 'cll', 'lymsm', 'transcend,(-nhl-001),(-nhl 001),(-nhl001),(-nhl-006),(-nhl 006),(-nhl006),(-pilot-017006),(-pilot017006),(-pilot 017006)', 'cml']
5) qol/pros from transcend cll (liso-cel in r/r cll). initial deterioration in qol and fatigue after car-t infusion, with clinically meaningful improvements at 3 months and sustained thereafter. #lymsm #celltherapy #17icml 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈